Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy

QR Code

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy

Kenji Inoue,1 Takayuki Fujimoto,1 Risako Higa,1 Ryo Moriyama,1 Hiromi Kohmoto,1 Haruka Nagumo,1 Masato Wakakura,1 Goji Tomita21Inouye Eye Hospital, Chiyoda-ku, Tokyo, 2Second Department of Ophthalmology, Toho University School of Medicine, Meguro-ku, Tokyo, JapanBackground: The purpose of this prosp...

Full description

Saved in:

Bibliographic Details
Main Authors:	Inoue K, Fujimoto T, Higa R, Moriyama R, Kohmoto H, Nagumo H, Wakakura M, Tomita G
Format:	article
Language:	EN
Published:	Dove Medical Press 2012
Subjects:	Ophthalmology RE1-994
Online Access:	https://doaj.org/article/d7396394d4dd4da983c6459d4d346c67
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
by: Inoue K, et al.
Published: (2014)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
by: Kanamoto T, et al.
Published: (2012)

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
by: Inoue K, et al.
Published: (2012)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
by: Yelda Buyru &Ouml;zkurt, et al.
Published: (2009)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
by: Douglas J Rhee, et al.
Published: (2008)

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
by: Radcliffe N, et al.
Published: (2020)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
by: Michael J Miyashiro, et al.
Published: (2010)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
by: David A Godfrey, et al.
Published: (2009)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
by: Mizoguchi T, et al.
Published: (2012)

Impacto sobre el tamaño de las muestras en estudios nacionales si cambiara el nivel de significación estadística de α= 0,05 a α = 0,005
by: Villarroel del Pino,Luis
Published: (2021)

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial
by: Brant Fernandes RA, et al.
Published: (2019)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
by: Inoue K, et al.
Published: (2015)

Sodium Hypochlorite 0.005% Versus Placebo in the Treatment of Mild to Moderate Acne: A Double-Blind Randomized Controlled Trial
by: Azadeh Dorostkar, et al.
Published: (2021)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs
by: Inoue K, et al.
Published: (2012)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
by: Mizoguchi T, et al.
Published: (2017)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
by: Turan-Vural E, et al.
Published: (2011)

Distinct domain switching in Nd0.05Ce0.95CoIn5 at low and high fields
by: D. G. Mazzone, et al.
Published: (2018)

The Bayes Factor, a Suitable Complement beyond Values of p<0.05 in Nursing Research and Education
by: Cristian Antony Ramos-Vera
Published: (2021)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
by: Deveney T, et al.
Published: (2018)

LiNi0.8Co0.15Al0.05O2: Enhanced Electrochemical Performance From Reduced Cationic Disordering in Li Slab
by: Peng Xiao, et al.
Published: (2017)

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
by: Arthur B Epstein, et al.
Published: (2009)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
by: Schnober D, et al.
Published: (2015)

Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
by: Palacio-Pastrana C, et al.
Published: (2020)

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily
by: Moisseiev E, et al.
Published: (2013)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
by: Costa VP, et al.
Published: (2012)

Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients
by: Alfredo Rossi, et al.
Published: (2020)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
by: Baiza-Dur&aacute;n LM, et al.
Published: (2012)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
by: Nicholas P Bell, et al.
Published: (2010)

Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination
by: Inoue K, et al.
Published: (2020)

Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®)
by: Katelin Quantz, et al.
Published: (2021)

A retrospective analysis of intraocular pressure changes after cataract surgery with the use of prednisolone acetate 1% versus difluprednate 0.05%
by: Kusne Y, et al.
Published: (2016)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
by: Burade V, et al.
Published: (2020)

Facile synthesis of g-C3N4(0.94)/CeO2(0.05)/Fe3O4(0.01) nanosheets for DFT supported visible photocatalysis of 2-Chlorophenol
by: Jamshaid Rashid, et al.
Published: (2019)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
by: Moataz E Gheith, et al.
Published: (2008)

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
by: Moisseiev E,&nbsp;Lazar M, et al.
Published: (2012)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
by: Lorenz K, et al.
Published: (2011)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
by: Rhee MK, et al.
Published: (2017)

Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
by: William Stringer, et al.
Published: (2010)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
by: Anne J Lee, et al.
Published: (2008)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
by: Maruyama Y, et al.
Published: (2015)